Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Gilead Sciences, Inc.
  6. News
  7. Press Releases
    GILD   US3755581036

GILEAD SCIENCES, INC.

(GILD)
  Report
Real-time Estimate Cboe BZX  -  05/24 11:21:35 am EDT
63.56 USD   -0.16%
05/23WALL STREET STOCK EXCHANGE : Biden comments reassure investors
05/23SVB Securities Initiates Gilead Sciences at Market Perform With $68 Price Target
MT
05/23ANALYST RECOMMANDATIONS : AbbVie, Amgen, Caterpillar, HP, Nike...
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société GILEAD SCIENCES, INC.
05/19Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Progr..
BU
05/17Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Car..
BU
05/17Gilead Sciences, Inc. - FDA Lifts Clinical Hold on Investigational Lenacapavir for the ..
AQ
05/16FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention..
BU
05/05GILEAD SCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
05/04GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/02Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Kille..
BU
04/28GILEAD SCIENCES : View First Quarter 2022 Supplementary Info
PU
04/28GILEAD SCIENCES : ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS - Form 8-K
PU
04/28GILEAD SCIENCES : View First Quarter 2022 Summary of Remarks
PU
04/28GILEAD SCIENCES : View First Quarter 2022 Earnings Release
PU
04/28GILEAD : Q1 Earnings Snapshot
AQ
04/28Gilead Sciences Announces First Quarter 2022 Financial Results
BU
04/26Gilead Sciences to Present at Upcoming Investor Conferences
BU
04/26Gilead Sciences, Inc. - Veklury (Remdesivir) is First and Only Approved Treatment for P..
AQ
04/25Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under..
BU
04/25Several New Studies Presented at ECCMIC 2022 Confirm Veklury (Remdesivir) Activity in T..
AQ
04/24Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in ..
BU
04/22Gilead Statement on WHO Recommendation of Veklury (Remdesivir) and Acceleration of Preq..
AQ
04/21GILEAD SCIENCES : Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleratio..
PU
04/19Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturin..
BU
04/14Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, ..
BU
04/13FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
AQ
04/12Gilead Sciences, Inc. - FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studi..
AQ
04/11FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
BU
04/04Yescarta Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment o..
AQ
04/01Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment ..
BU
03/28Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyo..
BU
03/24GILEAD SCIENCES : Annual Report Supplement - Corporate Information
PU
03/16Biopharma Stocks Targeting Crohn's Disease In $13.7 Billion Market (STAB, ARNA, GILD an..
AQ
03/15GILEAD SCIENCES : Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis ..
PU
03/11CAPITALGAINSREPORT : Biopharma Stocks Outperforming In $471 Billion Market (STAB, GILD, EX..
AQ
03/09GILEAD SCIENCES : to Expand Footprint in Oceanside
PU
03/07GILEAD SCIENCES : PHASE 3 TROPiCS-02 STUDY MET THE PRIMARY ENDPOINT OF PROGRESSION- FREE S..
PU
03/07Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-..
BU
03/07GILEAD SCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
03/02Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir ..
AQ
03/01Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir ..
BU
02/23GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
02/17Gilead Sciences, Inc. - New Clinical Data Support the Sustained Efficacy of Long-acting..
AQ
02/16New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's I..
BU
02/14Gilead Sciences, Inc. - Veklury (Remdesivir) Retains Antiviral Activity Against Omicron..
AQ
02/14Gilead Sciences, Inc. - Biktarvy Demonstrates High Efficacy and Durable Viral Suppressi..
AQ
02/14Gilead Sciences, Inc. - Phase 2/3 Interim Data Evaluating the Safety, Tolerability and ..
AQ
02/11GILEAD SCIENCES : View Q4 2021 Resource Book
PU
02/11Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Vek..
BU
02/11Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Tr..
BU
02/11Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emerg..
BU
02/10Takeda's Ramona Sequeira Becomes Board Chair of PhRMA
AQ
02/09Gilead Expands Availability of Veklury (remdesivir) to Non-Hospital Outpatient Faciliti..
AQ
02/09Gilead Sciences, Inc. to Help Dream Foundation Fulfill the Final Dreams of More Than 85..
AQ
02/08GILEAD SCIENCES : Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient..
PU
02/08Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressin..
BU
02/04GILEAD SCIENCES : Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient..
PU
02/03Gilead Sciences to Present at Upcoming Investor Conferences
BU
02/02Alphabet, Brinker International rise; PayPal, Gilead fall
AQ
02/02GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving li..
AQ
02/01GILEAD SCIENCES : View Q4 & Full Year 2021 Summary of Remarks
PU
02/01GILEAD : Q4 Earnings Snapshot
AQ
02/01GILEAD SCIENCES : View Q4 & Full Year 2021 Supplementary Info
PU
02/01GILEAD SCIENCES : Fourth Quarter 2021 Supplementary Info
PU
02/01GILEAD SCIENCES : ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS - Form 8-K
PU
02/01GILEAD SCIENCES : Announces Global Resolution of Bictegravir Patent Dispute with ViiV Heal..
PU
02/01GILEAD SCIENCES : View Q4 & Full Year 2021 Earnings Release
PU
02/01GILEAD SCIENCES : View Q4 & Full Year 2021 Presentation
PU
02/01Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
BU
02/01GILEAD SCIENCES INC : Results of Operations and Financial Condition (form 8-K)
AQ
02/01Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
BU
02/01U.s. fda approves new label update for car t-cell therapy yescarta showing prophylactic..
AQ
01/31U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylacti..
BU
01/31Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination..
AQ
01/25Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination..
BU
01/24Gilead Sciences-FDA Approves Veklury (Remdesivir) for the Treatment of Non-Hospitalized..
AQ
01/21FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at Hi..
BU
01/19GILEAD SCIENCES : Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply..
PU
1  2  3  4  5  6  7  8  9  10Next
Analysis
GSK to buy Sierra Oncology amid pressure to boost drug pipeline
Official Publications
04/28SEC Filing 10Q-1 
04/28Press Release 
04/281st quarter results 
04/28SEC Filing 8K 
03/07SEC Filing 8K 
03/03Report 
Upcoming event on GILEAD SCIENCES, INC.
06/02/22Bernstein Strategic Decisions Conference
Upcoming sector events
07/27/22VERTEX PHARMACEUTICALS INCORPORATED : Interim 2022 Earnings Release (Projected)
08/04/22REGENERON PHARMACEUTICALS, INC. : Interim 2022 Earnings Release (Projected)
08/08/22BIONTECH SE : Interim 2022 Earnings Release
08/23/22WUXI APPTEC CO., LTD. : Interim 2022 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs